Oncopeptides

Melflufen

Melflufen (INN melphalan flufenamide) is a first in class peptide-drug conjugate (PDC) that targets aminopeptidases and rapidly releases alkylating agents into tumor cells. Melflufen is rapidly taken up by myeloma cells due to its high lipophilicity and is immediately hydrolyzed by peptidases to release an entrapped hydrophilic alkylator payload.
Melflufen is an investigational drug and is not approved for commercial use.

Read more
Oncopeptides

Oncopeptides is a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat hematological diseases. The company is focusing on the development of the lead product candidate melflufen, a first in class peptide-drug conjugate (PDC) that targets aminopeptidases and rapidly releases alkylating agents into tumor cells.

Read more

Interim Report Q2 2020

Oncopeptides AB released its interim report for Q2 2020 on August 26, 2020.

Read the report

Press Releases

October 21, 2020Nomination committee in Oncopeptides established
October 19, 2020Oncopeptides has submitted an Investigational New Drug application to FDA for the second drug candidate from the PDC platform
October 14, 2020Oncopeptides signs € 40 million loan agreement with the EIB

All press releases

Calendar

Interim Report Q3 2020 November 19, 2020
Jefferies London Health Care Conference November 17, 2020 - November 19, 2020
DNB Nordic-American Virtual Life Science Conference December 3, 2020
62th ASH Annual Meeting & Exposition December 5, 2020 - December 8, 2020

All events

Audiocast regarding operational update Q2 2020

Oncopeptides held an operational update August 26, 2020. It was presented by CEO Marty J Duvall, CSO Jakob Lindberg and CFO Anders-Martin-Löf. The presentation was recorded.

See the webcast

Audiocast regarding operational update Q1 2020

Oncopeptides held an operational update Tuesday May 26, 2020. It was presented by CEO Jakob Lindberg and members of Oncopeptides management team. The presentation was recorded.